Background An open-label study indicated that selective depletion of B cells with the use of
rituximab led to sustained clinical improvements for patients with rheumatoid arthritis. To …

Recent insights in rheumatoid arthritis (RA) necessitated updating the European League
Against Rheumatism (EULAR) RA management recommendations. A large international Task …

Objectives To provide an update of the European League Against Rheumatism (EULAR)
rheumatoid arthritis (RA) management recommendations to account for the most recent …

Objective The 1987 American College of Rheumatology (ACR; formerly, the American
Rheumatism Association) classification criteria for rheumatoid arthritis (RA) have been criticized …

Background Neutralization of tumor necrosis factor α (TNF-α) for three to six months reduces
the symptoms and signs of rheumatoid arthritis. However, the capacity of this approach to …

Background Not all patients with rheumatoid arthritis can tolerate or respond to methotrexate,
a standard treatment for this disease. There is evidence that antitumour necrosis factor α (…

In this article, the 2010 European League against Rheumatism (EULAR) recommendations
for the management of rheumatoid arthritis (RA) with synthetic and biological disease-…

Background Aiming at therapeutic targets has reduced the risk of organ failure in many
diseases such as diabetes or hypertension. Such targets have not been defined for rheumatoid …

Objective To determine the efficacy and safety of treatment with rituximab plus methotrexate
(MTX) in patients with active rheumatoid arthritis (RA) who had an inadequate response to …

To identify new genetic risk factors for rheumatoid arthritis, we conducted a genome-wide
association study meta-analysis of 5,539 autoantibody-positive individuals with rheumatoid …